Log in

Relevant bibliographies by topics / Antiinfluenza / Journal articles

Journal articles on the topic 'Antiinfluenza'

To see the other types of publications on this topic, follow the link: Antiinfluenza.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antiinfluenza.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Covés-Datson, Evelyn M., Steven R. King, Maureen Legendre, Auroni Gupta, Susana M. Chan, Emily Gitlin, Vikram V. Kulkarni, et al. "A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo." Proceedings of the National Academy of Sciences 117, no. 4 (January 13, 2020): 2122–32. http://dx.doi.org/10.1073/pnas.1915152117.

Full text

Abstract:

There is a strong need for a new broad-spectrum antiinfluenza therapeutic, as vaccination and existing treatments are only moderately effective. We previously engineered a lectin, H84T banana lectin (H84T), to retain broad-spectrum activity against multiple influenza strains, including pandemic and avian, while largely eliminating the potentially harmful mitogenicity of the parent compound. The amino acid mutation at position 84 from histidine to threonine minimizes the mitogenicity of the wild-type lectin while maintaining antiinfluenza activity in vitro. We now report that in a lethal mouse model H84T is indeed nonmitogenic, and both early and delayed therapeutic administration of H84T intraperitoneally are highly protective, as is H84T administered subcutaneously. Mechanistically, attachment, which we anticipated to be inhibited by H84T, was only somewhat decreased by the lectin. Instead, H84T is internalized into the late endosomal/lysosomal compartment and inhibits virus–endosome fusion. These studies reveal that H84T is efficacious against influenza virus in vivo, and that the loss of mitogenicity seen previously in tissue culture is also seen in vivo, underscoring the potential utility of H84T as a broad-spectrum antiinfluenza agent.

APA, Harvard, Vancouver, ISO, and other styles

2

DeGoey, David A., Hui-Ju Chen, William J. Flosi, David J. Grampovnik, Clinton M. Yeung, Larry L. Klein, and Dale J. Kempf. "Enantioselective Synthesis of Antiinfluenza Compound A-315675." Journal of Organic Chemistry 67, no. 16 (August 2002): 5445–53. http://dx.doi.org/10.1021/jo0162890.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Traynor, Kate. "Antiinfluenza medication kits need work, FDA advisers conclude." American Journal of Health-System Pharmacy 65, no. 24 (December 15, 2008): 2314–16. http://dx.doi.org/10.2146/news080098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sznaidman, Marcos L., Eric A. Meade, Lilia M. Beauchamp, Stuart Russell, and Margaret Tisdale. "The antiinfluenza activity of pyrrolo[2,3-d]pyrimidines." Bioorganic & Medicinal Chemistry Letters 6, no. 5 (March 1996): 565–68. http://dx.doi.org/10.1016/0960-894x(96)00070-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mokrushina, G. A., S. K. Kotovskaya, G. N. Tyurenkova, V. I. Il'enko, V. G. Platonov, and I. V. Kiseleva. "Synthesis of 2-hydrazinobenzimidazoles and their antiinfluenza activity." Pharmaceutical Chemistry Journal 22, no. 2 (February 1988): 146–50. http://dx.doi.org/10.1007/bf00758445.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ge, Hu, Yi-Fei Wang, Jun Xu, Qiong Gu, Hai-Bo Liu, Pei-Gen Xiao, Jiaju Zhou, Yanhuai Liu, Zirong Yang, and Hua Su. "ChemInform Abstract: Antiinfluenza Agents from Traditional Chinese Medicine." ChemInform 42, no. 13 (March 3, 2011): no. http://dx.doi.org/10.1002/chin.201113269.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Dyason, Jeffrey C., and Mark von Itzstein. "ChemInform Abstract: Antiinfluenza Virus Drug Design: Sialidase Inhibitors." ChemInform 33, no. 29 (May 20, 2010): no. http://dx.doi.org/10.1002/chin.200229266.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zhang, Chun Jing, and Hai Tao Yu. "The Signal Pathways of Immune Inflammation Mediated by the Tlr3/Nf-Kappab and Activator Protein-1 in Cells Infected with Influenza A Virus Antagonized by Baicalin." Advanced Materials Research 345 (September 2011): 201–9. http://dx.doi.org/10.4028/www.scientific.net/amr.345.201.

Full text

Abstract:

Baicalin has better anti-inflammatory function, antioxidant function and antiviral activity, but the mechanism of the antiinfluenza viral activity of baicalin has not been revealed.Toll-like Receptor 3 and the signal pathways mediated by TLR3 were affected and controlled by the infections with influenza A virus. We report here the significant activity and part mechanism of baicalin against H3N2 influenza A viruses. Baicalin could well protect the damages of cells caused by influenza A virus, it also could effectively inhibit the production of CPE in cells caused by influenza A virus and the inhibition of cells growth. The mechanism of antiinfluenza virus infection of baicalin may be related with the following aspects: to decrease the transcriptional activity of the oxidative stress sensitive transcription factor NF-kappaB and AP-1 by moderately decrease the higher expression level of TLR3 mRNA and the higher expression level of protein; and to further inhibit the mRNA expression of the downstream target genes IL-1β, IL-8, RANTES and IFN-β thereby alleviate the inflammatory injuries and restore the stability and balance of immune function in vivro.

APA, Harvard, Vancouver, ISO, and other styles

9

Yoo, Jae-Kwang, Carole L. Galligan, Carl Virtanen, and Eleanor N. Fish. "Identification of a novel antigen-presenting cell population modulating antiinfluenza type 2 immunity." Journal of Experimental Medicine 207, no. 7 (June 14, 2010): 1435–51. http://dx.doi.org/10.1084/jem.20091373.

Full text

Abstract:

Antiinfluenza type 2 (T2) immunity contributes to both immunopathology and immunoprotection, yet the underlying mechanisms modulating T2 immunity remain ill defined. We describe a novel mouse antigen (Ag)-presenting cell (APC), designated late-activator APC (LAPC). After pulmonary influenza A (H1N1) virus infection, LAPCs enter the lungs, capture viral Ag, and subsequently migrate to the draining lymph node (DLN) and spleen, with delayed kinetics relative to dendritic cells (DCs). In the DLN, influenza virus–activated LAPCs present Ag and selectively induce T helper type 2 (Th2) effector cell polarization by cell–cell contact–mediated modulation of GATA-3 expression. In adoptive transfer experiments, influenza virus–activated LAPCs augmented Th2 effector T cell responses in the DLN, increased production of circulating antiinfluenza immunoglobulin, and increased levels of T2 cytokines in bronchoalveolar lavage fluid in recipient influenza virus–infected mice. LAPC-recipient mice exhibited exacerbated pulmonary pathology, with delayed viral clearance and enhanced pulmonary eosinophilia. Collectively, our results identify and highlight the importance of LAPCs as immunomodulators of T2 immunity during influenza A virus infection.

APA, Harvard, Vancouver, ISO, and other styles

10

Tuttle, Joel V., Margaret Tisdale, and Thomas A. Krenitsky. "Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents." Journal of Medicinal Chemistry 36, no. 1 (January 1993): 119–25. http://dx.doi.org/10.1021/jm00053a015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

GOMES, LUCY. "Fatores de risco e medidas profiláticas nas pneumonias adquiridas na comunidade." Jornal de Pneumologia 27, no. 2 (March 2001): 97–114. http://dx.doi.org/10.1590/s0102-35862001000200008.

Full text

Abstract:

Este artigo revisa os efeitos do envelhecimento, tabagismo, DPOC, insuficiência cardíaca, colonização da orofaringe, aspiração (micro e macro), alcoolismo, cirrose hepática, deficiência nutricional, imunossupressão e fatores ambientais sobre o risco de adquirir pneumonia na comunidade e sua gravidade. Na segunda parte, é feita revisão sobre a ação profilática das vacinas antiinfluenza e antipneumococo, assim como a ação das drogas antivirais, na profilaxia e tratamento das pneumonias adquiridas na comunidade.

APA, Harvard, Vancouver, ISO, and other styles

12

Felix, Felippe, Geraldo Augusto Gomes, Gustavo Augusto Porto Sereno Cabral, Jamerson Reis Cordeiro, and Shiro Tomita. "O papel de novas vacinas na prevenção da otite média." Revista Brasileira de Otorrinolaringologia 74, no. 4 (August 2008): 613–16. http://dx.doi.org/10.1590/s0034-72992008000400021.

Full text

Abstract:

A Otite Média é uma das doenças infecciosas mais comuns da infância e a diminuição de sua incidência levaria a um grande impacto econômico e social para o mundo. Como uma das formas de prevenção temos as vacinas. As duas vacinas escolhidas para esta revisão são as vacinas antipneumocócica e antiinfluenza. Esta revisão da literatura procurou mostrar os resultados dos principais estudos sobre essas vacinas e seu papel na prevenção da otite média. A vacina antipneumocócica polissacarídea 23-valente não alterou a incidência de otite média pela ineficácia para menores de 2 anos, grupo de maior incidência dessa enfermidade. A vacina antipneumocócica heptavalente, apesar de não provocar grande queda na incidência geral de otite média, mudou o perfil de seus microorganismos causadores, diminuindo os episódios de otite média com efusão e recorrente e aumentando as otites causadas por H. influenza, M. catarrhalis e sorotipos de pneumococo ausentes da vacina heptavalente. A vacina antiinfluenza com vírus inativado mostrou-se efetiva na redução da otite média aguda nos períodos de maior incidência desse vírus. Os otorrinolaringologistas devem estar cientes do papel dessas novas vacinas já disponíveis no Brasil e seu impacto na redução da otite média, para saber orientar adequadamente os seus pacientes.

APA, Harvard, Vancouver, ISO, and other styles

13

Sevy, Alexander M., Nicholas C. Wu, Iuliia M. Gilchuk, Erica H. Parrish, Sebastian Burger, Dina Yousif, Marcus B. M. Nagel, et al. "Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses." Proceedings of the National Academy of Sciences 116, no. 5 (January 14, 2019): 1597–602. http://dx.doi.org/10.1073/pnas.1806004116.

Full text

Abstract:

Influenza is a yearly threat to global public health. Rapid changes in influenza surface proteins resulting from antigenic drift and shift events make it difficult to readily identify antibodies with broadly neutralizing activity against different influenza subtypes with high frequency, specifically antibodies targeting the receptor binding domain (RBD) on influenza HA protein. We developed an optimized computational design method that is able to optimize an antibody for recognition of large panels of antigens. To demonstrate the utility of this multistate design method, we used it to redesign an antiinfluenza antibody against a large panel of more than 500 seasonal HA antigens of the H1 subtype. As a proof of concept, we tested this method on a variety of known antiinfluenza antibodies and identified those that could be improved computationally. We generated redesigned variants of antibody C05 to the HA RBD and experimentally characterized variants that exhibited improved breadth and affinity against our panel. C05 mutants exhibited improved affinity for three of the subtypes used in design by stabilizing the CDRH3 loop and creating favorable electrostatic interactions with the antigen. These mutants possess increased breadth and affinity of binding while maintaining high-affinity binding to existing targets, surpassing a major limitation up to this point.

APA, Harvard, Vancouver, ISO, and other styles

14

Alvear Téllez, Gonzalo. "Is there bias in the current recommendations for influenza vaccine?" Medwave 13, no. 10 (November 30, 2013): e5848-e5848. http://dx.doi.org/10.5867/medwave.2013.10.5848.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Rubini, Norma. "Riscos da vacinação antiinfluenza em crianças com infecção pelo HIV." Jornal de Pediatria 79, no. 1 (February 2003): 5–6. http://dx.doi.org/10.1590/s0021-75572003000100003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

ISOBE, HIDEKI, FREDERICK ALT, CONSTANTIN A. BONA, and JEROME SCHULMAN. "Intact Antiinfluenza Virus Immune Response in Targeted κ-Deficient Mice." Viral Immunology 7, no. 1 (January 1994): 25–30. http://dx.doi.org/10.1089/vim.1994.7.25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ponomarenko, A. I., and G. S. Skripchenko. "The practical value of the antiinfluenza antibodies electrokinetic potential determination." Immunology Letters 56 (May 1997): 305. http://dx.doi.org/10.1016/s0165-2478(97)86229-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ponomarenko, A. "The practical value of the antiinfluenza antibodies electrokinetic potential determination." Immunology Letters 56, no. 1-3 (May 1997): 305. http://dx.doi.org/10.1016/s0165-2478(97)88067-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Serkedjieva, Julia, Svetla Danova, and Iskra Ivanova. "Antiinfluenza Virus Activity of a Bacteriocin Produced by Lactobacillus delbrueckii." Applied Biochemistry and Biotechnology 88, no. 1-3 (2000): 285–98. http://dx.doi.org/10.1385/abab:88:1-3:285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Serkedjieva, Julia, Monika Konaklieva, Stefka Dimitrova-Konaklieva, Veneta Ivanova, Kamen Stefanov, and Simeon Popov. "Antiinfluenza Virus Effect of Extracts from Marine Algae and Invertebrates." Zeitschrift für Naturforschung C 55, no. 1-2 (February 1, 2000): 87–93. http://dx.doi.org/10.1515/znc-2000-1-217.

Full text

Abstract:

Abstract Sixty products, derived from marine organisms, typical of the Bulgarian Black Sea coast, were examined for inhibitory activity on the reproduction of influenza viruses in tissue cultures. The antiviral effect was investigated by the reduction of virus infectivity. Using representative strains of influenza virus it was shown that apparently the inhibitory effect was strain-specific. The most effective products were further studied in fertile hen’s eggs and in experimental influenza infection in white mice.

APA, Harvard, Vancouver, ISO, and other styles

21

Nguyen, Huu Tung, Hyuk-Joon Kwon, Jae-Hong Kim, Jeong Chan Ra, Yan Ding, Jeong Ah Kim, and Young Ho Kim. "ChemInform Abstract: Antiinfluenza Diarylheptanoids from the Bark of Alnus japonica." ChemInform 41, no. 38 (August 26, 2010): no. http://dx.doi.org/10.1002/chin.201038217.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

DeGoey, David A., Hui-Ju Chen, William J. Flosi, David J. Grampovnik, Clinton M. Yeung, Larry L. Klein, and Dale J. Kempf. "ChemInform Abstract: Enantioselective Synthesis of Antiinfluenza Compound A-315675 (I)." ChemInform 33, no. 50 (May 18, 2010): no. http://dx.doi.org/10.1002/chin.200250081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Serkedjieva, Julia. "Combined antiinfluenza virus activity ofFlos verbasci infusion and amantadine derivatives." Phytotherapy Research 14, no. 7 (2000): 571–74. http://dx.doi.org/10.1002/1099-1573(200011)14:7<571::aid-ptr653>3.0.co;2-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

SZNAIDMAN, M. L., E. A. MEADE, L. M. BEAUCHAMP, S. RUSSELL, and M. TISDALE. "ChemInform Abstract: The Antiinfluenza Activity of Pyrrolo(2,3-d)pyrimidines." ChemInform 27, no. 28 (August 5, 2010): no. http://dx.doi.org/10.1002/chin.199628196.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Choi, Hwa Jung, Jae Hyoung Song, and Dur Han Kwon. "Quercetin 3-rhamnoside Exerts Antiinfluenza A Virus Activity in Mice." Phytotherapy Research 26, no. 3 (July 5, 2011): 462–64. http://dx.doi.org/10.1002/ptr.3529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Mauldin, Scott C., William J. Hornback, and John E. Munroe. "ChemInform Abstract: Synthesis of Pentenoic Acid Analogues as Potential Antiinfluenza Agents." ChemInform 32, no. 42 (May 24, 2010): no. http://dx.doi.org/10.1002/chin.200142095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Kabanov, A., A. O. Sementsova, M. O. Skarnovich, T. V. Teplyakova, L. N. Shishkina, and A. N. Sergeev. "Development of new effective antiinfluenza drugs based on extracts of basidiomycetes." International Journal of Infectious Diseases 14 (March 2010): e88. http://dx.doi.org/10.1016/j.ijid.2010.02.1684.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

ROHLOFF, J. C., and ET AL ET AL. "ChemInform Abstract: Practical Total Synthesis of the Antiinfluenza Drug GS-4104." ChemInform 29, no. 46 (June 19, 2010): no. http://dx.doi.org/10.1002/chin.199846233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Feng, Enguang, Deju Ye, Jian Li, Dengyou Zhang, Jinfang Wang, Fei Zhao, Rolf Hilgenfeld, Mingyue Zheng, Hualiang Jiang, and Hong Liu. "ChemInform Abstract: Recent Advances in Neuraminidase Inhibitor Development as Antiinfluenza Drugs." ChemInform 43, no. 45 (October 11, 2012): no. http://dx.doi.org/10.1002/chin.201245260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Watanabe, Kazuhiro, Junji Sakurai, Hideki Abe, and Tadashi Katoh. "ChemInform Abstract: Total Synthesis of (+)-Stachyflin: A Potential Antiinfluenza A Virus Agent." ChemInform 41, no. 43 (September 30, 2010): no. http://dx.doi.org/10.1002/chin.201043202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kosik, Ivan, Davide Angeletti, Jmes S. Gibbs, Mathew Angel, Kazuyo Takeda, Martina Kosikova, Vinod Nair, et al. "Neuraminidase inhibition governs protection efficacy of broadly neutralizing antiinfluenza hemagglutinin stem antibodies." Journal of Immunology 202, no. 1_Supplement (May 1, 2019): 139.20. http://dx.doi.org/10.4049/jimmunol.202.supp.139.20.

Full text

Abstract:

Abstract There is enormous interest in improving influenza A virus immunization. The most promising target for “universal” flu vaccination is the conserved stem region of the viral hemagglutinin (HA). The HA stem is the target for the vast majority of broadly neutralizing (BN) monoclonal antibodies (Abs). It is well established that BNHA Abs can prevent fusion of the viral and endosomal membranes. A discrepancy between in vitro vs. in vivo efficacy, however, suggests additional mechanisms of action. Recent studies support the role of the BNHA Abs Fc interaction with innate immune effector cells. Here we show that BNHA mAbs potently inhibit viral neuraminidase (NA) activity against large substrates. To unravel the biological relevance of this activity, we created a panel of recombinant IAVs with shorter or longer NA stalks. Finding that neuraminidase inhibition (NI) activity is inversely proportional to NA stalk length, we use these viruses to show that the NI activity of BNHA Abs is responsible for their ability to block virus release from cells and enhanced neutralization. Critically, we show that NA stalk length governs in vivo protection mediated by BNHA Abs in mice, providing a completely novel mechanism for BNHA Abs in vivo activity. In addition, we demonstrated that the NI activity of BNHA Abs enhances the ability of virus-Ab complexes to activate Fc receptor-bearing cells, and further, that FDA approved small molecule NA inhibitors have a similar effect on Fc-mediated innate immune cell activation, providing a novel mechanism for their clinical activity. Altogether, our findings provide surprising and clinically relevant insights into the in vivo mechanisms of protection provided by both anti-stem BN antibodies and NA inhibitors.

APA, Harvard, Vancouver, ISO, and other styles

32

Shan, Yuanyuan, Ying Ma, Maoyi Wang, and Yalin Dong. "Recent Advances in the Structure-Based Design of Neuraminidase Inhibitors as Antiinfluenza Agents." Current Medicinal Chemistry 19, no. 34 (November 1, 2012): 5885–94. http://dx.doi.org/10.2174/092986712804143358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Wagner, Koen, Mark J. Kwakkenbos, Yvonne B. Claassen, Kelly Maijoor, Martino Böhne, Koenraad F. van der Sluijs, Martin D. Witte, et al. "Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity." Proceedings of the National Academy of Sciences 111, no. 47 (November 10, 2014): 16820–25. http://dx.doi.org/10.1073/pnas.1408605111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Serkedjieva, J. "Combined Antiinfluenza Virus Effect of a Plant Preparation and a Bacterial Protease Inhibitor." Biotechnology & Biotechnological Equipment 23, sup1 (January 2009): 589–93. http://dx.doi.org/10.1080/13102818.2009.10818494.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Slepushkin, Anatoly N., Elena I. Bourtseva, Alexey L. Belyaev, Liliya N. Vlassova, and Elena L. Feodoritova. "Influenza morbidity and some peculiarities of antiinfluenza immunity and prevention during influenza pandemics." International Congress Series 1263 (June 2004): 787–90. http://dx.doi.org/10.1016/j.ics.2004.01.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Zhang, Jingyu, Dandan Lu, Aixing Li, Jing Yang, and Shengqi Wang. "ChemInform Abstract: Design, Synthesis and Antiinfluenza Virus Activities of Terminal Modified Antisense Oligonucleotides." ChemInform 45, no. 12 (March 6, 2014): no. http://dx.doi.org/10.1002/chin.201412220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Maamary, Jad, Taia T. Wang, Gene S. Tan, Peter Palese, and Jeffrey V. Ravetch. "Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization." Proceedings of the National Academy of Sciences 114, no. 38 (September 5, 2017): 10172–77. http://dx.doi.org/10.1073/pnas.1707950114.

Full text

Abstract:

The main barrier to reduction of morbidity caused by influenza is the absence of a vaccine that elicits broad protection against different virus strains. Studies in preclinical models of influenza virus infections have shown that antibodies alone are sufficient to provide broad protection against divergent virus strains in vivo. Here, we address the challenge of identifying an immunogen that can elicit potent, broadly protective, antiinfluenza antibodies by demonstrating that immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV) can elicit broadly protective antihemagglutinin antibodies. Further, we found that an Fc-modified, bispecific monoclonal antibody against conserved epitopes of the hemagglutinin can be combined with TIV to elicit broad protection, thus setting the stage for a universal influenza virus vaccine.

APA, Harvard, Vancouver, ISO, and other styles

38

Colacino, J. M., and J. C. Tang. "The search for antiinfluenza compounds with specific reference to LY217896 and its sodium salt." Drugs of the Future 17, no. 11 (1992): 1019. http://dx.doi.org/10.1358/dof.1992.017.11.194702.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Kai, Hiroyuki, Hiroshi Matsumoto, Naohiko Hattori, Akira Takase, Tamio Fujiwara, and Hirohiko Sugimoto. "ChemInform Abstract: Antiinfluenza Virus Activities of 2-Alkoxyimino-N-(2-isoxazolin-3-ylmethyl)acetamides." ChemInform 32, no. 44 (May 24, 2010): no. http://dx.doi.org/10.1002/chin.200144138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Honda, Takeshi, Takeshi Masuda, Shuku Yoshida, Masami Arai, Yoshiyuki Kobayashi, and Makoto Yamashita. "ChemInform Abstract: Synthesis and Antiinfluenza Virus Activity of 4-Guanidino-7-substituted Neu5Ac2en Derivatives." ChemInform 33, no. 45 (May 19, 2010): no. http://dx.doi.org/10.1002/chin.200245184.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Fukami, Akiko, Tomonori Nakamura, Yong-Pil Kim, Kazuro Shiomi, Masahiko Hayashi, Takayuki Nagai, Haruki Yamada, Kanki Komiyama, and Satoshi Omura. "ChemInform Abstract: A New Antiinfluenza Virus Antibiotic, 10-Norparvulenone from Microsphaeropsis sp. FO-5050." ChemInform 32, no. 9 (February 27, 2001): no. http://dx.doi.org/10.1002/chin.200109234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Piquer-Gibert, M., A. Plaza-Martín, A. Martorell-Aragonés, L. Ferré-Ybarz, L. Echeverría-Zudaire, J. Boné-Calvo, and S. Nevot-Falcó. "Recommendations for administering the triple viral vaccine and antiinfluenza vaccine in patients with egg allergy." Allergologia et Immunopathologia 35, no. 5 (September 2007): 209–12. http://dx.doi.org/10.1157/13110316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Honda, Takeshi, Takeshi Masuda, Shuku Yoshida, Masami Arai, Satoru Kaneko, and Makoto Yamashita. "ChemInform Abstract: Synthesis and Antiinfluenza Virus Activity of 7-O-Alkylated Derivatives Related to Zanamivir." ChemInform 33, no. 45 (May 19, 2010): no. http://dx.doi.org/10.1002/chin.200245185.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Oka, Mitsuru, Yoshiro Ishiwata, Noriyuki Iwata, Naoki Honda, and Takuji Kakigami. "ChemInform Abstract: Synthesis and Antiinfluenza Virus Activity of Tricyclic Compounds with a Unique Amine Moiety." ChemInform 32, no. 39 (May 24, 2010): no. http://dx.doi.org/10.1002/chin.200139123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Jin, Yi, Yuewei Zhang, Chunyan Wan, Hongjun Wang, Lingyu Hou, Jianyu Chang, Kai Fan, and Xiangming Xie. "Immunomodulatory Activity and Protective Effects of Polysaccharide fromEupatorium adenophorumLeaf Extract on Highly Pathogenic H5N1 Influenza Infection." Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/194976.

Full text

Abstract:

The development of novel broad-spectrum, antiviral agents against H5N1 infection is urgently needed. In this study, we evaluated the immunomodulatory activities and protective effect ofEupatorium adenophorumpolysaccharide (EAP) against the highly pathogenic H5N1 subtype influenza virus. EAP treatment significantly increased the production of IL-6, TNF-α, and IFN-γbothin vivoandin vitroas measured by qPCR and ELISA. In a mouse infection model, intranasal administration of EAP at a dose of 25 mg/kg body weight prior to H5N1 viral challenge efficiently inhibited viral replication, decreased lung lesions, and increased survival rate. We further evaluated the innate immune recognition of EAP, as this process is regulated primarily Dectin-1 and mannose receptor (MR). These results indicate that EAP may have immunomodulatory properties and a potential prophylactic effect against H5N1 influenza infection. Our investigation suggests an alternative strategy for the development of novel antiinfluenza agents and benefits ofE. adenophorumproducts.

APA, Harvard, Vancouver, ISO, and other styles

46

Cesarone, Maria Rosaria, Gianni Belcaro, Andrea Di Renzo, Mark Dugall, Marisa Cacchio, Irma Ruffini, Luciano Pellegrini, et al. "Prevention of Influenza Episodes With Colostrum Compared With Vaccination in Healthy and High-Risk Cardiovascular Subjects." Clinical and Applied Thrombosis/Hemostasis 13, no. 2 (April 2007): 130–36. http://dx.doi.org/10.1177/1076029606295957.

Full text

Abstract:

The efficacy of a 2-month treatment with oral colostrum in the prevention of flu episodes compared with antiinfluenza vaccination was evaluated. Groups included healthy subjects without prophylaxis and those receiving both vaccination and colostrum. After 3 months of follow-up, the number of days with flu was 3 times higher in the non-colostrum subjects. The colostrum group had 13 episodes versus 14 in the colostrum + vaccination group, 41 in the group without prophylaxis, and 57 in nontreated subjects. Part 2 of the study had a similar protocol with 65 very high-risk cardiovascular subjects, all of whom had prophylaxis. The incidence of complications and hospital admission was higher in the group that received only a vaccination compared with the colostrum groups. Colostrum, both in healthy subjects and high-risk cardiovascular patients, is at least 3 times more effective than vaccination to prevent flu and is very cost-effective.

APA, Harvard, Vancouver, ISO, and other styles

47

Ashraf, Usama, Laura Tengo, Laurent Le Corre, Guillaume Fournier, Patricia Busca, Andrew A. McCarthy, Marie-Anne Rameix-Welti, et al. "Destabilization of the human RED–SMU1 splicing complex as a basis for host-directed antiinfluenza strategy." Proceedings of the National Academy of Sciences 116, no. 22 (May 10, 2019): 10968–77. http://dx.doi.org/10.1073/pnas.1901214116.

Full text

Abstract:

New therapeutic strategies targeting influenza are actively sought due to limitations in current drugs available. Host-directed therapy is an emerging concept to target host functions involved in pathogen life cycles and/or pathogenesis, rather than pathogen components themselves. From this perspective, we focused on an essential host partner of influenza viruses, the RED–SMU1 splicing complex. Here, we identified two synthetic molecules targeting an α-helix/groove interface essential for RED–SMU1 complex assembly. We solved the structure of the SMU1 N-terminal domain in complex with RED or bound to one of the molecules identified to disrupt this complex. We show that these compounds inhibiting RED–SMU1 interaction also decrease endogenous RED-SMU1 levels and inhibit viral mRNA splicing and viral multiplication, while preserving cell viability. Overall, our data demonstrate the potential of RED-SMU1 destabilizing molecules as an antiviral therapy that could be active against a wide range of influenza viruses and be less prone to drug resistance.

APA, Harvard, Vancouver, ISO, and other styles

48

Chand, Pooran, Pravin L. Kotian, Ali Dehghani, Yahya El-Kattan, Tsu-Hsing Lin, Tracy L. Hutchison, Y. Sudhakar Babu, Shanta Bantia, Arthur J. Elliott, and John A. Montgomery. "Systematic Structure-Based Design and Stereoselective Synthesis of Novel Multisubstituted Cyclopentane Derivatives with Potent Antiinfluenza Activity." Journal of Medicinal Chemistry 44, no. 25 (December 2001): 4379–92. http://dx.doi.org/10.1021/jm010277p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wang, Pei, and John Z. H. Zhang. "Selective Binding of Antiinfluenza Drugs and Their Analogues to ‘Open’ and ‘Closed’ Conformations of H5N1 Neuraminidase." Journal of Physical Chemistry B 114, no. 40 (October 14, 2010): 12958–64. http://dx.doi.org/10.1021/jp1030224.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Bozzini, Tiziana, Giorgia Botta, Michela Delfino, Silvano Onofri, Raffaele Saladino, Donatella Amatore, Rossella Sgarbanti, Lucia Nencioni, and Anna Teresa Palamara. "Tyrosinase and Layer-by-Layer supported tyrosinases in the synthesis of lipophilic catechols with antiinfluenza activity." Bioorganic & Medicinal Chemistry 21, no. 24 (December 2013): 7699–708. http://dx.doi.org/10.1016/j.bmc.2013.10.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!